- Home
- OMH vs MBIO Comparison
OMH vs MBIO Comparison
Compare OMH & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OMH | MBIO |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.6M | 4.7M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | OMH | MBIO |
|---|---|---|
| Price | $0.98 | $1.19 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 42.8K | ★ 90.7K |
| Earning Date | 11-28-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $10,264,748.00 | N/A |
| Revenue This Year | $28.40 | N/A |
| Revenue Next Year | $23.07 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 78.86 | N/A |
| 52 Week Low | $0.59 | $0.89 |
| 52 Week High | $4.53 | $13.29 |
Technical Indicators
Market Signals| Indicator | OMH | MBIO |
|---|---|---|
| Relative Strength Index (RSI) | 58.68 | 52.32 |
| Support Level | $0.80 | $1.07 |
| Resistance Level | $0.87 | $1.15 |
| Average True Range (ATR) | 0.06 | 0.07 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 78.67 | 85.19 |
Price Performance
Historical ComparisonAbout OMH Ohmyhome Limited
Ohmyhome Ltd is a data and technology-driven property technology company based in Singapore. Through its subsidiaries, it operates a one-stop-shop property platform that provides end-to-end property solutions and services for its customers, which comprises brokerage services and emerging and other services, such as home renovation and furnishing services, listing and research, mortgage referral, legal services, and insurance referral services. The company derives its revenues from two sources: revenue from brokerage services, property management services, and revenue from emerging and other services.
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.